As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during late November 2022.